Endometrial carcinoma, particularly early-onset endometrioid endometrial carcinoma (EEEC), is increasingly prevalent among younger women, necessitating a focus on fertility preservation and molecular characterization. A comprehensive multi-omics study involving 215 patients, including 81 with EEEC, revealed critical molecular insights that could predict responses to fertility-sparing therapies (ref: Hu doi.org/10.1038/s41588-024-01703-z/). Additionally, the molecular characterization of endometrial cancer (EC) has emerged as a pivotal factor in developing prognostic signatures and therapeutic strategies, especially considering that 5-10% of EC cases are hereditary, predominantly linked to Lynch syndrome (ref: D'Agostino doi.org/10.1016/j.ctrv.2024.102723/). Furthermore, the clinical and genomic landscape of RAS mutations in gynecologic cancers has been explored, highlighting their implications for survival and treatment strategies, with a focus on the association between RAS mutation status and overall survival rates (ref: Son doi.org/10.1158/1078-0432.CCR-23-2819/). The Endometrioid Endometrial RNA Index has also been identified as a promising tool for predicting recurrence in stage I patients, emphasizing the potential of genomic and transcriptomic data in improving patient outcomes (ref: Nief doi.org/10.1158/1078-0432.CCR-23-3158/).